Loading
Chemotherapy-related Skin Toxicity · Journal article
British Journal of Clinical Pharmacology · September 8, 2026
Encouraging direction, but not yet definitive.
This single-centre RCT randomized 40 breast cancer patients to prophylactic alpha lipoic acid (300 mg three times daily for 3 weeks) or no intervention, and found ALA reduced the incidence and severity of radiation-induced dermatitis by RTOG grading, with a biomarker signal in IL-6. The trial is methodologically sound but small and single-blinded, supporting promise rather than practice change without larger confirmation.
Randomized controlled trial, single-blinded. Breast cancer patients scheduled for radiotherapy; 40 total enrolled. Intervention: Alpha lipoic acid 300 mg three times daily for 3 weeks starting on first day of radiotherapy. Compared with: No prophylaxis for radiation-induced dermatitis. n = 40. Not stated.
At week 2, 90% of ALA patients remained asymptomatic versus 50% in control; at week 3, 60% versus 20% Grade ≥2 RID occurred in 10% of ALA patients versus 45% in control Serum IL-6 was significantly lower in ALA group at end of study (p = 0.044)
ALA was safe and well-tolerated with no reported adverse events
If confirmed in larger trials, prophylactic ALA may reduce clinically bothersome radiation dermatitis in breast cancer patients undergoing radiotherapy. Current evidence is insufficient to recommend routine adoption pending replication and assessment of long-term dermatitis outcomes.
A single-centre RCT with modest sample size (n=40) and surrogate endpoint (dermatitis grading) showing benefit of ALA over control, needing confirmation in larger trials before clinical adoption.
As stated by the source record.
Quoted from the source exactly as published.
If confirmed in larger trials, prophylactic ALA may reduce clinically bothersome radiation dermatitis in breast cancer patients undergoing radiotherapy. Current evidence is insufficient to recommend routine adoption pending replication and assessment of long-term dermatitis outcomes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
BACKGROUND: Radiation-induced dermatitis (RID) is an important side effect that occurs in 95% of patients receiving radiation therapy. The purpose of this study was to evaluate the efficacy and safety of alpha lipoic acid (ALA) in preventing RID in breast cancer patients. METHODS: In this randomized-controlled, single-blinded trial, 40 patients with breast cancer who were scheduled for radiotherapy were randomly allocated to ALA group (n = 20) who received 300 mg ALA three times daily starting at the first day of radiotherapy for 3 weeks or control group (n = 20) who did not receive any prophylaxis for RID. Primary outcomes were the incidence and severity of RID using Radiation Therapy Oncology Group (RTOG) grading criteria. Secondary outcomes were maximum grade of RID and changes in serum concentrations of interleukin-6 (IL-6). RESULTS: In ALA group, 90% and 60% of patients remained asymptomatic at the end of the second and third weeks of radiotherapy compared to 50% and 20%, respectively, in the control group. Moreover, only 10% of patients in ALA group developed ≥ grade 2 RID compared to 45% in control. A significant reduction in the serum levels of IL-6 was observed in the ALA group at the end of the study compared to control (p = 0.044). ALA was safe and well-tolerated. CONCLUSION: Prophylactic administration of ALA significantly delayed the onset and reduced the severity of RID besides its anti-inflammatory effect in breast cancer patients.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.